Business
INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis at COSM 2023
Safety and Immunological data from both cohorts of the recently completed Phase 1/2 trial will be presented on May 5th PLYMOUTH MEETING, Pa., April 27, 2023
About this update from Inovio Pharmaceuticals, Inc.
[{"type":"text","content":"Safety and Immunological data from both cohorts of the recently completed Phase 1/2 trial will be presented on May 5th\nPLYMOUTH MEETING, Pa., April 27, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that an abstract has been accepted for oral presentation on INO-3107 for the treatment of Recurrent Respiratory Papillomatosis (RRP) at this year's American Broncho-Esophagological Association (ABEA) program at the Combined Otolaryngology Spring Meetings (COSM) in Boston, Massachusetts.\n\"We are pleased that lead investigator Dr. Ted Mau will have the opportunity to share additional encouraging insights on the safety and immunogenicity of INO-3107 from both cohorts of our recently completed study,\" said Dr. Mike Sumner, INOVIO's Chief Medical Officer.\nDetails of the ABEA at COSM presentation are as follows:\nTitle: Phase 1/2 Open-label, Multicenter Trial Of INO-3107 With Electroporation In Adult Patients With HPV-6 And/or HPV-11-associated Recurrent Respiratory Papillomatosis: Interim AnalysisSession: ABEA Scientific Session III: Voice Session Date and Time: Friday, May 5, 2023, 9:00 am EDT Location: 304/306 (Hynes)\nThe presentation will include new safety, immunological, and demographic data from both cohorts of a Phase 1/2 trial evaluating the safety, tolerability, immunogenicity, and efficacy of INO-3107 in 32 patients with HPV-6 and/or HPV-11-associated RRP.\nAbout RRP\nRRP is a debilitating and rare disease caused primarily by HPV-6 and/or HPV-11. RRP is characterized by the development of small, wart-like growths, or papillomas, in the respiratory tract. While papillomas are generally benign, they can cause severe, life-threatening airway obstruction and respiratory complications. RRP can also significantly affect quality of life for patients by affecting the voice box, limiting the ability to speak effectively. Surgery to remove papillomas is the standard of care for RRP; however, the papillomas often grow back because the underlying HPV infection has not been eradicated.\nThe most widely cited U.S. epidemiology data from 1995 cites 14,000 active cases and about 1.8 per 100,000 new cases in adults each year. More recent pediatric epidemi...